Surface-Functionalized Silica-Coated Calcium Phosphate Nanoparticles Efficiently Deliver DNA-Based HIV-1 Trimeric Envelope Vaccines against HIV-1
Authors:
- 4 November 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 13 (45) , 53630-53645
Abstract
Human immunodeficiency virus type 1 (HIV-1) infection remains one of the worst crises in global health. The prevention of HIV-1 infection is a crucial task that needs to be addressed due to the absence of a licensed vaccine against HIV-1. DNA vaccines present a promising alternative approach to combat HIV-1 infection due to their excellent safety profile, lack of severe side effects, and relatively rapid fabrication. Traditional vaccines composed of a monomeric envelope or peptide fragments have been indicated to lack protective efficacy mediated by inducing HIV-1-specific neutralizing antibodies in clinical trials. The immunogenicity and protection against HIV-1 induced by DNA vaccines are limited due to the poor uptake of these vaccines by antigen-presenting cells and their ready degradation by DNases and lysosomes. To address these issues of naked DNA vaccines, we described the feasibility of CpG-functionalized silica-coated calcium phosphate nanoparticles (SCPs) for efficiently delivering DNA-based HIV-1 trimeric envelope vaccines against HIV-1. Vaccines comprising the soluble BG505 SOSIP.664 trimer fused to the GCN4-based isoleucine zipper or bacteriophage T4 fibritin foldon motif with excellent simulation of the native HIV-1 envelope were chosen as trimer-based vaccine platforms. Our results showed that SCP-based DNA immunization could significantly induce both broad humoral immune responses and potent cellular immune responses compared to naked DNA vaccination in vivo. To the best of our knowledge, this study is the first to assess the feasibility of CpG-functionalized SCPs for efficiently delivering DNA vaccines expressing a native-like HIV-1 trimer. These CpG-functionalized SCPs for delivering DNA-based HIV-1 trimeric envelope vaccines may lead to the development of promising vaccine candidates against HIV-1.Keywords
Funding Information
- National Natural Science Foundation of China (31770996)
This publication has 50 references indexed in Scilit:
- Diminutive effect on T and B-cell proliferation of non-cytotoxic α-santonin derived 1,2,3-triazoles: A reportEuropean Journal of Medicinal Chemistry, 2013
- Surface-Engineered Gold Nanorods: Promising DNA Vaccine Adjuvant for HIV-1 TreatmentNano Letters, 2012
- Mesoporous Silica‐Coated Gold Nanorods as a Light‐Mediated Multifunctional Theranostic Platform for Cancer TreatmentAdvanced Materials, 2012
- A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cellsRetrovirology, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or MicrobicidesJournal of Biological Chemistry, 2010
- Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea PigsJournal of Virology, 2010
- DNA vaccines: precision tools for activating effective immunity against cancerNature Reviews Cancer, 2008
- The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccineBiomaterials, 2008
- Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, ThailandThe Journal of Infectious Diseases, 2006